Sionna Posts $32.4M Q3 Loss; $249.8M Cash Funds Operations Into 2H 2029
SION is trading near its 52-week low of $3.19 (10% above the low).
Summary
Sionna reported a $32.4M Q3 2026 net loss and $249.8M in cash, extending its runway into the second half of 2029, and said it will start the AscenSION CF Phase 2 trial of SION-451 + SION-2222 in Q1 2027.
Key Events · Earnings and Guidance · SION
-
Q3 Loss Widens to $32.4M
Net loss was $32.4M, or $0.72 per share, versus $20.3M a year earlier, driven by R&D of $22.0M and G&A of $12.8M including restructuring costs from the September workforce cut.
-
Cash Runway Extended to 2H 2029
Cash, cash equivalents and marketable securities totaled $249.8M at September 30, 2026, which management expects to fund operations into the second half of 2029.
-
AscenSION CF Phase 2 Set for Q1 2027
The open-label proof-of-concept trial of SION-451 + SION-2222 in F508del-homozygous patients will start in the first quarter of 2027, assessing sweat chloride, safety and PK over 28 days after switching from Trikafta.
-
Post Hoc Data Support NBD1 Activity
Excluding three participants with exposures consistent with dosing non-adherence, PreciSION CF showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L when SION-719 was added to Trikafta.
Analysis · SION · Life Sciences
Investors now have the first hard numbers since Sionna cut 46% of its staff in September and narrowed its focus to the SION-451 + SION-2222 dual combination. The loss widened to $32.4M from $20.3M a year ago on higher R&D and restructuring costs, but $249.8M of cash now stretches the runway into the second half of 2029 — roughly two and a half years beyond the prior 2028 guide. That removes any near-term financing pressure and turns the unused $250M ATM into a backstop rather than a necessity. The key forward item is the AscenSION CF Phase 2 proof-of-concept trial, now slated to start in Q1 2027; that readout is what the story hinges on, and the delay-free timeline plus extended cash means the company can fund it without selling stock at $3.52.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SION was trading at $3.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $161.4M. The 52-week trading range was $3.19 to $54.97. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.